Join us at the product slam:

Friday, October 2, 2020

10:50 – 11:50

Canopy Biosciences (most recently acquired by Bruker Corp.) is offering a comprehensive portfolio of genomic and proteomic products and services. One of the key technologies at Canopy focuses on multiplexed immune biomarker detection in cells and intact tissue samples via ChipCytometry. ChipCytometry is a unique cytometry technology enabling the biobanking of precious samples and the re-interrogative and non-destructive detection of markers at highest sensitivity and over a large dynamic range of 8 logs without suffering from the know freeze-bias of other technologies.

Speaker: Dr. Kurt Herrenknecht
Director Business Development – Europe | Canopy Biosciences

Additional information is available at

and at